Cyclic depsipeptide antibiotic aureobasidin A (AbA) and its analogs were tested for the inhibitory activity of P-glycoprotein in multidrug resistant cancer cells as well as for the antifungal activity. Some analogs with lower antifungal activity than AbA showed higher inhibition of P-glycoproteins indicating difference of the structure-activity methylvalyl9]-AbA newly prepared by chemical synthesis, which had much lower antifungal activity than AbA, showed 10-fold higher inhibitory activity of P-glycoprotein than AbA.
Aureobasidin A (AbA, Fig. 1 The resistance of tumor cells to several structurally unrelated chemotherapeutic drugs is a serious barrier to the treatment of human cancers. The multidrug resistance of tumors is caused through overexpression of a 170kDa plasma membrane protein, the P-glycoprotein belonging to ATP-binding cassette (ABC) transporters superfamily. 7) There 
AbA by hydrogen fluoride treatment, was digested with proline- AbA showed higher P-glycoprotein inhibitory activity having much less antifungal activity than AbA showed higher inhibition of P-glycoprotein than it.4) Replacement of Phe at residue 3 of [D-MeAla4]-AbA with Tyr derivatives caused reduction of the P-glycoprotein inhibitory activity regardless of enhancing the activity against C. neoformans. These results indicate difference of the structure-activity relationships between the antifungal activity and the inhibition of P-glycoprotein.
AbA (Fig. 2) . We determined its IC50 value of Pglycoprotein inhibition using MCF-7/mdr. The IC50 The inhibitory activity to MCF-7/mdr cells of most of aureobasidins was superior to that of AD10 cells. This may be due to difference in the expression levels or the type of P-glycoproteins between the two cells, or in the substrates used for the assays. Mammalian cells have several ABC transporters and the multidrug resistance of tumor cells is caused by overexpression of either of two types of ABC transporters, MDR1 P-glycoprotein or multidrug resistance-associated protein (MRP1). 
